These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 31629254)

  • 1. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
    Zhang X; Qi Y; Zhang Q; Liu W
    Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A proteogenomic approach to target neoantigens in solid tumors.
    Verma A; Halder A; Marathe S; Purwar R; Srivastava S
    Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
    Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDENTIFICATION OF MHC PEPTIDES USING MASS SPECTROMETRY FOR NEOANTIGEN DISCOVERY AND CANCER VACCINE DEVELOPMENT.
    Chen R; Fulton KM; Twine SM; Li J
    Mass Spectrom Rev; 2021 Mar; 40(2):110-125. PubMed ID: 31875992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward in silico Identification of Tumor Neoantigens in Immunotherapy.
    Zhou C; Zhu C; Liu Q
    Trends Mol Med; 2019 Nov; 25(11):980-992. PubMed ID: 31494024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
    Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
    J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy.
    Ren Y; Yue Y; Li X; Weng S; Xu H; Liu L; Cheng Q; Luo P; Zhang T; Liu Z; Han X
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113147. PubMed ID: 39270345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens.
    Polyakova A; Kuznetsova K; Moshkovskii S
    Expert Rev Proteomics; 2015; 12(5):533-41. PubMed ID: 26175083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in immunopeptidomic-based tumor neoantigen discovery.
    Meng W; Schreiber RD; Lichti CF
    Adv Immunol; 2023; 160():1-36. PubMed ID: 38042584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteogenomic Platform for Identification of Tumor Specific Antigens.
    Faktor J; Hernychová L; Vojtěšek B; Hupp T
    Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
    Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
    Front Immunol; 2021; 12():662443. PubMed ID: 33936100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioinformatic methods for cancer neoantigen prediction.
    Boegel S; Castle JC; Kodysh J; O'Donnell T; Rubinsteyn A
    Prog Mol Biol Transl Sci; 2019; 164():25-60. PubMed ID: 31383407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy.
    Li G; Mahajan S; Ma S; Jeffery ED; Zhang X; Bhattacharjee A; Venkatasubramanian M; Weirauch MT; Miraldi ER; Grimes HL; Sheynkman GM; Tilburgs T; Salomonis N
    Sci Transl Med; 2024 Jan; 16(730):eade2886. PubMed ID: 38232136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
    Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
    Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides.
    Admon A; Barnea E; Ziv T
    Mol Cell Proteomics; 2003 Jun; 2(6):388-98. PubMed ID: 12821722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
    Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
    Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
    Yao P; Gao M; Hu W; Wang J; Wang Y; Wang Q; Ji J
    Pharmacol Res; 2024 Jun; 204():107209. PubMed ID: 38740147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
    De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
    Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.